NCT05695976

GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide (TMZ) to Evaluate Tumor Response Via Liquid Biopsies (GRETeL)

• Status: Suspended
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor characteristics, and/or peripheral immunosuppression.

Conditions

• Glioblastoma
• Glioma, Malignant

Timeline

• Start date: 2023-04-18
• Primary completion: 2029-01-01
• Completion: 2029-01-01
• First posted: 2023-01-25
• Last updated: 2025-05-28

Locations

1 site across 1 country: United States